AOD-9604 vs 5-Amino-1MQ

Side-by-side comparison

How they differ in mechanism

AOD-9604 is a synthetic peptide corresponding to the C-terminal region of human growth hormone with a tyrosine substitution. The published preclinical literature reports lipolytic activity and increased fat oxidation in obese rodent models without the growth-promoting or diabetogenic effects of intact growth hormone. The fragment does not engage the growth hormone receptor, and the specific signalling pathway mediating its lipolytic effects remains incompletely characterised in the published literature.

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase, an enzyme that methylates nicotinamide to form 1-methylnicotinamide. NNMT is expressed at high levels in white adipose tissue, and the published preclinical literature reports that inhibition of NNMT increases intracellular NAD+ availability, modulates SAM/SAH methylation ratios, and shifts adipocyte metabolism toward increased energy expenditure. The Neelakantan and Dimet-Wiley studies have characterised these effects in cell-culture and diet-induced-obesity rodent models.

The two compounds operate through entirely unrelated pathways. AOD-9604 is a peptide acting through an undefined lipolytic mechanism. 5-Amino-1MQ is a small molecule acting through enzyme inhibition in the NAD+ and methyl-donor metabolic network. They share the broad research theme of fat-metabolism modulation but have no mechanistic intersection in the published literature.

How research has examined each

The AOD-9604 literature concentrates on the Heffernan studies from the early 2000s demonstrating fat oxidation and weight loss in obese mice. A more recent study by Kwon and colleagues examined AOD-9604 in intra-articular injection for osteoarthritis in a rabbit model. The human pharmacology literature is sparse, and the compound did not advance through large-scale Phase 3 development for metabolic indications.

The 5-Amino-1MQ literature is concentrated in the Neelakantan fluorescent assay work establishing the NNMT inhibition mechanism, and in the Dimet-Wiley dietary-restriction-plus-NNMT-inhibition rodent studies. The broader NNMT biology literature provides context on the enzyme’s role in adipose-tissue metabolism, NAD+ homeostasis, and cellular energy balance. Both the compound-specific and the enzyme-biology literatures are at the preclinical stage.

Both compounds are positioned at an early stage of evidence development. Neither has a mature Phase 3 clinical program. Researchers interested in fat-metabolism modulation through novel pathways read both literatures as part of the broader investigational-compound landscape, but the mechanistic pathways are unrelated and the model systems are different.

Stacking considerations in research contexts

Combined administration of AOD-9604 and 5-Amino-1MQ is not described in the published research literature. The mechanisms are unrelated (lipolytic peptide fragment versus NNMT enzyme inhibitor), so there is no anticipated receptor-level collision, but no published protocol describes the combination. Both compounds are available as separate vials in the Ronin catalog (AOD-9604 at 5 mg, 5-Amino-1MQ at 50 mg) for researchers to source independently.

Sourcing both at Ronin

Both compounds in the Ronin catalog ship as lyophilised material in glass vials, capped and crimped, with certificate-of-analysis documentation (mass spec + HPLC purity) on the lab-results page. The AOD-9604 vial page ships at 5 mg per vial. The 5-Amino-1MQ vial page ships at 50 mg per vial. Both carry per-compound spec sheets and storage guidance. Both are sold strictly as research-grade reagents for laboratory and bench-research applications.

Frequently asked research questions

References

1. Heffernan MA et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity, 2001. [PMID 11673763]
2. Wilding J. AOD-9604 Metabolic. Current Opinion in Investigational Drugs, 2004. [PMID 15134286]
3. Neelakantan H et al. Noncoupled Fluorescent Assay for Direct Real-Time Monitoring of Nicotinamide N-Methyltransferase Activity. Biochemistry, 2017. [PMID 28121423]
4. Dimet-Wiley A et al. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Scientific Reports, 2022. [PMID 35013352]
5. Kwon DR et al. Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Annals of Clinical and Laboratory Science, 2015. [PMID 26275694]